Overview

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
VU University Medical Center
Collaborator:
Celgene
Treatments:
Cyclophosphamide
Dexamethasone